{"id":"NCT00411684","sponsor":"HRA Pharma","briefTitle":"Safety and Efficacy of CDB-2914 for Emergency Contraception","officialTitle":"A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-04-08","completion":"2009-06-05","firstPosted":"2006-12-14","resultsPosted":"2021-05-03","lastUpdate":"2021-09-21"},"enrollment":1623,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Emergency Contraception"],"interventions":[{"type":"DRUG","name":"CDB-2914","otherNames":[]}],"arms":[{"label":"CDB-2914","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.","primaryOutcome":{"measure":"Pregnancy Rate","timeFrame":"Up to 60 days after enrollment","effectByArm":[{"arm":"CDB-2914","deltaMin":2.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":12},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":["20093897"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":1533},"commonTop":["Headache","Nausea","Abdominal pain","Dysmenorrhea","Dizziness"]}}